Investor Relations (IR) Questions: Synthetic Biologics SYN
Click here to return to the biotech IRQ Index
Answers received: September 2012
1) When is the last time SYN raised cash through an offering (diluted)?
The last time SYN raised cash was in April 2011.
2) How much cash (not cash equivalents) does SYN have?
In our 2nd Q 2012 10-Q, we disclosed that we had cash as follows: ~$5.9 million at the quarter end (6/30/2012) and ~$5.6 million at 7/31/2012.
3) What and approximately when is the next known catalyst?
In August 2012, we announced that we expanded our relationship with Intrexon Corporation by entering into a second worldwide exclusive channel collaboration for the development and commercialization of a series of monoclonal antibody (mAb) therapies for the treatment of certain infectious diseases not adequately addressed by existing therapies. Utilizing Intrexon’s comprehensive suite of proprietary technologies, initial discovery efforts will target three infectious disease indications. Earlier this week, we announced the first of the three infectious disease targets, the pathogen, Acinetobacter. In the near-term, we expect to announce the other two infectious disease targets.
4) What is SYN's quarterly cash burn?
Based on the 2nd Q 2012 10-Q filing, our cash burn is approximately $1.3 million per quarter.
5) Does SYN have an existing line of credit and if so how much can they draw against it?
Per the 2nd Q 2012 10-Q filing, we do not have debt or a line of credit reported on our balance sheet.
1) When is the last time SYN raised cash through an offering (diluted)?
The last time SYN raised cash was in April 2011.
2) How much cash (not cash equivalents) does SYN have?
In our 2nd Q 2012 10-Q, we disclosed that we had cash as follows: ~$5.9 million at the quarter end (6/30/2012) and ~$5.6 million at 7/31/2012.
3) What and approximately when is the next known catalyst?
In August 2012, we announced that we expanded our relationship with Intrexon Corporation by entering into a second worldwide exclusive channel collaboration for the development and commercialization of a series of monoclonal antibody (mAb) therapies for the treatment of certain infectious diseases not adequately addressed by existing therapies. Utilizing Intrexon’s comprehensive suite of proprietary technologies, initial discovery efforts will target three infectious disease indications. Earlier this week, we announced the first of the three infectious disease targets, the pathogen, Acinetobacter. In the near-term, we expect to announce the other two infectious disease targets.
4) What is SYN's quarterly cash burn?
Based on the 2nd Q 2012 10-Q filing, our cash burn is approximately $1.3 million per quarter.
5) Does SYN have an existing line of credit and if so how much can they draw against it?
Per the 2nd Q 2012 10-Q filing, we do not have debt or a line of credit reported on our balance sheet.